Siren LLC’s Benitec Biopharma BNTC Stock Holding History

Siren LLC’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-775,000	Closed	-$10.4M	–	106
2025 Q4	$10.4M	Buy	+775,000	New	+$10.7M	0.31%	53

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Siren LLC's BNTC Position: Q1 2026 in Review

Siren LLC sold out of Benitec Biopharma (BNTC) in Q1 2026, closing a stake of 775,000 shares — an estimated $10.4M sold.

Siren LLC first reported a position in BNTC in Q4 2025 and held it in 1 quarter. The position peaked at $10.4M in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

Siren LLC reported no remaining Benitec Biopharma position as of Q1 2026 after selling out during the quarter.
Siren LLC sold 775,000 Benitec Biopharma shares in Q1 2026, an estimated $10.4M.
Siren LLC first reported a position in Benitec Biopharma in Q4 2025 and held it in 1 quarter.
Siren LLC's Benitec Biopharma position peaked at $10.4M in Q4 2025.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Siren LLC's 13F filing for Q1 2026, filed 14 May 2026.